- ResMed presents with near-term upside potential not yet reflected by the market.
- The upside case is bolstered by a key competitor's withdrawal from the market until 2023 at least.
- This adds to the certainty of RMD's future cash flows and underpins interesting economics in the company's forward sales estimates.
- We are seeking a return objective of $35 per share with a speculative buy rating, aiming to capture the near-term catalyst listed above.
For further details see:
ResMed: Near-Term Upside From Philips Withdrawal, Seeking $35 Per Share Return Objective